– CytoAgents was awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year.
– The funding will accelerate the development of its lead drug candidate, GP1681, an investigational new drug that targets hypercytokinemia, more commonly known as “cytokine storm.”
– Scientific consensus is building that overwhelming inflammation and severe illness is triggered by a phenomenon known as cytokine storm, a severe form of cytokine release syndrome when an excessive immune response attacks the body.
– CytoAgents mission is to develop a broadly accessible treatment for multiple indications of high unmet need of cytokine storm, including for Cytokine Release Syndrome (CRS) in CAR T-cell therapy and in COVID-19 patients.